Viyash Scientific reported a strong Q1 FY27 with net profit soaring 115% to Rs 79 crore. Revenue grew 20% to Rs 946 crore, and EBITDA jumped 59%. The company also significantly reduced its net debt.
Viyash Scientific Posts Robust Q1 FY27 Results
Rs. 946 crore Revenue (+20% YoY); Rs. 79 crore PAT (+115% YoY). Reader Takeaway: Strong profit growth and balance sheet deleveraging; acquisition execution is key. ## What just happened Viyash Scientific Limited announced its financial results for the first quarter of FY27, ending June 30, 2026. The company reported a significant 115% year-on-year increase in Profit After Tax (PAT), reaching Rs. 79 crore, up from Rs. 37 crore in the same period last year. Revenue from operations grew by 20% year-on-year to Rs. 946 crore. ## Why this matters The strong performance indicates improved operational efficiency and profitability. The substantial PAT growth, coupled with a significant reduction in net debt to EBITDA ratio to 0.1x from 1x, signals a healthier financial position. This deleveraging and profit surge are positive indicators for shareholders. ## The backstory The company has completed the integration of its business units, which it states was done in record time. Growth in its Animal Health Formulation business and US Business, driven by a focus on backward-integrated and complex products, has been strong. The API business saw flat growth due to raw material price volatility. ## What changes now Viyash Scientific has signed an agreement to acquire Bio For Life in Italy, which is expected to provide direct market access for companion animal health products. Management has provided guidance for FY27, expecting mid-teen growth (13%-15%) and setting a long-term revenue aspiration of $1 billion by 2032. ## Risks to watch While the company is confident, the flat performance in the API business due to raw material price volatility and timing needs monitoring. The successful integration and scaling of the acquired Italian entity will be crucial for achieving long-term growth targets. ## Peer comparison (No direct peer comparison data available in the filing) ## Context metrics (time-bound) - **Revenue (Q1 FY27):** Rs. 946 crore (+20% YoY) - **EBITDA (Q1 FY27):** Rs. 205 crore (+59% YoY) - **EBITDA Margin (Q1 FY27):** 21.6% (+530 bps YoY) - **PAT (Q1 FY27):** Rs. 79 crore (+115% YoY) - **Net Debt/EBITDA (Q1 FY27):** 0.1x (down from 1x YoY) - **Finance Costs (Q1 FY27):** Rs. 12.5 crore (down from Rs. 20.4 crore YoY) ## What to track next Investors will be looking for the closure of the Bio For Life acquisition in Italy and its subsequent impact on revenue and market access. Monitoring the recovery and growth in the API business and execution of the company's ambitious long-term revenue targets will also be key.
